| Typicality: | 0.412 |
| Saliency: | 0.000 |
| during the clinical trial | 3 | temporal |
| assay → be used to characterize → the end-point assays | 3 |
| negative | neutral | positive |
| 0.007 | 0.764 | 0.229 |
| Raw frequency | 3 |
| Normalized frequency | 0.000 |
| Modifier score | 1.000 |
| Perplexity | 42.506 |